VLA 0.00% $1.75 viralytics limited

we value viralytics at a$0.69/share, page-22

  1. 91 Posts.
    lightbulb Created with Sketch. 15
    No. The surgical complete responses are not recorded as part of the complete responses in the Phase II trial. These are part of the extension trial. The results appear to be significant, given that the only 2 patients that have completed the extension study have been able to have the remaining tumours removed. There are another 3 currently in the extension trial, hopefully they have a similar outcome.

    This information has been reported in the recent media releases.
 
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.